The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable activity against chronic lymphocytic leukemia B cells with CD20 antibodies.
作者信息
Golay Josée, Ubiali Greta, Introna Martino
机构信息
Center of Cellular Therapy "G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy
Center of Cellular Therapy "G. Lanzani, USC Hematology, and Fondazione per la Ricerca Ospedale Maggiore, ASST Papa Giovanni XXIII, Bergamo, Italy.
出版信息
Haematologica. 2017 Oct;102(10):e400-e403. doi: 10.3324/haematol.2017.169334. Epub 2017 Jun 22.
Abstract
摘要
相似文献
1
The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable activity against chronic lymphocytic leukemia B cells with CD20 antibodies.特异性布鲁顿酪氨酸激酶抑制剂阿卡替尼（ACP-196）与CD20抗体联合使用时，对慢性淋巴细胞白血病B细胞显示出良好的活性。
Haematologica. 2017 Oct;102(10):e400-e403. doi: 10.3324/haematol.2017.169334. Epub 2017 Jun 22.
2
Acalabrutinib: First Global Approval.阿卡替尼：全球首次获批。
Drugs. 2018 Jan;78(1):139-145. doi: 10.1007/s40265-017-0852-8.
3
Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.阿卡替尼及其在慢性淋巴细胞白血病治疗中的应用。
Future Oncol. 2019 Feb;15(6):579-589. doi: 10.2217/fon-2018-0637. Epub 2018 Nov 1.
4
Second-generation inhibitors of Bruton tyrosine kinase.布鲁顿酪氨酸激酶第二代抑制剂
J Hematol Oncol. 2016 Sep 2;9(1):80. doi: 10.1186/s13045-016-0313-y.
5
Acalabrutinib, A Second-Generation Bruton's Tyrosine Kinase Inhibitor.阿卡拉布替尼，第二代布鲁顿酪氨酸激酶抑制剂。
Recent Results Cancer Res. 2018;212:285-294. doi: 10.1007/978-3-319-91439-8_14.
6
Acalabrutinib: a highly selective, potent Bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia.阿卡替尼：一种高选择性、强效布鲁顿酪氨酸激酶抑制剂，用于治疗慢性淋巴细胞白血病。
Leuk Lymphoma. 2021 May;62(5):1066-1076. doi: 10.1080/10428194.2020.1864352. Epub 2021 Jan 11.
7
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.阿卡拉布替尼（ACP-196）：一种具有独特选择性和体内药效学特征的共价布鲁顿酪氨酸激酶抑制剂。
J Pharmacol Exp Ther. 2017 Nov;363(2):240-252. doi: 10.1124/jpet.117.242909. Epub 2017 Sep 7.
8
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.阿卡替尼（ACP-196）：一种选择性第二代布鲁顿酪氨酸激酶（BTK）抑制剂。
J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.
9
Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.血管医学影像。一名接受阿卡拉布替尼治疗的慢性淋巴细胞白血病患者的鲁姆佩尔-利德现象。
Vasc Med. 2020 Jun;25(3):281-282. doi: 10.1177/1358863X19901166. Epub 2020 Mar 7.
10
Combined BTK and PI3Kδ Inhibition with Acalabrutinib and ACP-319 Improves Survival and Tumor Control in CLL Mouse Model.阿卡替尼联合 BTK 和 PI3Kδ 抑制剂 ACP-319 可改善 CLL 小鼠模型的生存和肿瘤控制。
Clin Cancer Res. 2017 Oct 1;23(19):5814-5823. doi: 10.1158/1078-0432.CCR-17-0650. Epub 2017 Jun 23.
引用本文的文献
1
Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.一线使用阿卡替尼、来那度胺和利妥昔单抗治疗高肿瘤负荷的晚期滤泡性淋巴瘤：II期试验
Nat Commun. 2025 Aug 7;16(1):7300. doi: 10.1038/s41467-025-62509-z.
2
Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).阿卡拉布替尼联合利妥昔单抗和来那度胺治疗复发或难治性滤泡性淋巴瘤患者：1b期开放标签研究（ACE-LY-003）结果
Br J Haematol. 2025 Mar;206(3):887-898. doi: 10.1111/bjh.19951. Epub 2024 Dec 12.
3
First-line therapy for high-risk people with chronic lymphocytic leukemia: a network meta-analysis.高危慢性淋巴细胞白血病患者的一线治疗：网络荟萃分析。
Cochrane Database Syst Rev. 2024 Oct 30;10(10):CD015169. doi: 10.1002/14651858.CD015169.
4
Unveiling the Cardiotoxicity Conundrum: Navigating the Seas of Tyrosine Kinase Inhibitor Therapies.揭示心脏毒性之谜：探索酪氨酸激酶抑制剂治疗的海洋。
Cancer Control. 2024 Jan-Dec;31:10732748241285755. doi: 10.1177/10732748241285755.
5
Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.阿卡替尼单药或联合利妥昔单抗治疗滤泡性淋巴瘤：一项开放标签研究。
Br J Haematol. 2024 Dec;205(6):2248-2253. doi: 10.1111/bjh.19787. Epub 2024 Sep 22.
6
XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.XPO1 抑制使 CLL 细胞对 NK 细胞介导的细胞毒性敏感，并克服 HLA-E 的表达。
Leukemia. 2023 Oct;37(10):2036-2049. doi: 10.1038/s41375-023-01984-z. Epub 2023 Aug 1.
7
Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis.布鲁顿酪氨酸激酶抑制剂单药治疗与联合治疗慢性淋巴细胞白血病和小淋巴细胞淋巴瘤的疗效与安全性：一项系统评价和荟萃分析
Cancers (Basel). 2023 Mar 27;15(7):1996. doi: 10.3390/cancers15071996.
8
Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities.慢性淋巴细胞白血病中的下一代布鲁顿酪氨酸激酶抑制剂：不断演变的挑战与新机遇
Cancers (Basel). 2023 Feb 27;15(5):1504. doi: 10.3390/cancers15051504.
9
Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia.阿卡替尼联合高频低剂量皮下利妥昔单抗治疗慢性淋巴细胞白血病的初始疗法。
Blood Adv. 2023 Jun 13;7(11):2496-2503. doi: 10.1182/bloodadvances.2022009382.
10
Natural Killer Cells in Chronic Lymphocytic Leukemia: Functional Impairment and Therapeutic Potential.慢性淋巴细胞白血病中的自然杀伤细胞：功能损害与治疗潜力
Cancers (Basel). 2022 Nov 24;14(23):5787. doi: 10.3390/cancers14235787.
本文引用的文献
1
Comparison of Acalabrutinib, A Selective Bruton Tyrosine Kinase Inhibitor, with Ibrutinib in Chronic Lymphocytic Leukemia Cells.选择性布鲁顿酪氨酸激酶抑制剂阿卡拉布替尼与依鲁替尼在慢性淋巴细胞白血病细胞中的比较。
Clin Cancer Res. 2017 Jul 15;23(14):3734-3743. doi: 10.1158/1078-0432.CCR-16-1446. Epub 2016 Dec 29.
2
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶（BTK）抑制剂阿卡替尼在两种慢性淋巴细胞白血病小鼠模型中显示出强效的靶向作用和疗效。
Clin Cancer Res. 2017 Jun 1;23(11):2831-2841. doi: 10.1158/1078-0432.CCR-16-0463. Epub 2016 Nov 30.
3
Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.激酶抑制剂依鲁替尼用于预防抗CD19嵌合抗原受体T细胞治疗B细胞肿瘤后发生的细胞因子释放综合征。
Leukemia. 2017 Jan;31(1):246-248. doi: 10.1038/leu.2016.262. Epub 2016 Sep 28.
4
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.新型布鲁顿酪氨酸激酶（BTK）抑制剂阿卡替尼在犬B细胞非霍奇金淋巴瘤模型中的临床前评估
PLoS One. 2016 Jul 19;11(7):e0159607. doi: 10.1371/journal.pone.0159607. eCollection 2016.
5
Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.阿卡替尼（ACP-196）：一种选择性第二代布鲁顿酪氨酸激酶（BTK）抑制剂。
J Hematol Oncol. 2016 Mar 9;9:21. doi: 10.1186/s13045-016-0250-9.
6
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.阿卡替尼（ACP-196）用于复发的慢性淋巴细胞白血病
N Engl J Med. 2016 Jan 28;374(4):323-32. doi: 10.1056/NEJMoa1509981. Epub 2015 Dec 7.
7
Interactions between Ibrutinib and Anti-CD20 Antibodies: Competing Effects on the Outcome of Combination Therapy.伊布替尼与抗CD20抗体之间的相互作用：对联合治疗结果的竞争效应。
Clin Cancer Res. 2016 Jan 1;22(1):86-95. doi: 10.1158/1078-0432.CCR-15-1304. Epub 2015 Aug 17.
8
Ibrutinib impairs the phagocytosis of rituximab-coated leukemic cells from chronic lymphocytic leukemia patients by human macrophages.依鲁替尼会损害人巨噬细胞对来自慢性淋巴细胞白血病患者的利妥昔单抗包被的白血病细胞的吞噬作用。
Haematologica. 2015 Apr;100(4):e140-2. doi: 10.3324/haematol.2014.119669. Epub 2015 Jan 23.
9
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy.依鲁替尼干扰治疗性CD20抗体的细胞介导抗肿瘤活性：对联合治疗的启示。
Haematologica. 2015 Jan;100(1):77-86. doi: 10.3324/haematol.2014.107011. Epub 2014 Oct 24.
10
Current concepts in the diagnosis and management of cytokine release syndrome.细胞因子释放综合征的诊断和治疗的当前概念。
Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182/blood-2014-05-552729. Epub 2014 May 29.
Zotero 插件